title: SLFN11: Achilles' Heel or Troublemaker.
abstract: SLFN11 expression correlates with sensitivity of tumors to topoisomerase and DNA-targeting drugs and consequently with prognosis. Regulation of SLFN11 by ETS factors opens new avenues to treatment optimization, maximizing antitumor activity and minimizing adverse side effects. Interrogating drug-induced gene expression signatures for SLFN11 modulations may affect the design of therapeutic regimens.
authors.affiliation: Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria. Department of Pediatrics, Medical University, Vienna, Austria. heinrich.kovar@ccri.at.
authors.forename: Heinrich
authors.initials: H
authors.lastname: Kovar
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009687:Nuclear Proteins / Q000235:genetics* / Q000378:metabolism*; D015514:Oncogene Proteins, Fusion / Q000378:metabolism*; D051789:Proto-Oncogene Protein c-fli-1 / Q000378:metabolism*; D034802:RNA-Binding Protein EWS / Q000378:metabolism*; D012512:Sarcoma, Ewing / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D009687:Nuclear Proteins; D015514:Oncogene Proteins, Fusion; D051789:Proto-Oncogene Protein c-fli-1; D034802:RNA-Binding Protein EWS